<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150393</url>
  </required_header>
  <id_info>
    <org_study_id>MPOH05</org_study_id>
    <nct_id>NCT04150393</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Evaluation of MaaT033</brief_title>
  <acronym>CIMON</acronym>
  <official_title>Safety Phase I Evaluation of MaaT033, a Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule, In HeMatOlogy Malignant Patients Under iNtensive Chemotherapy (CIMON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaaT Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaaT Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Richness and diversity of gut microbiota are increasingly found to be associated with cancer&#xD;
      outcomes. Moreover, an adequately responsive immune system seems to rely on the existence of&#xD;
      a functioning gut ecosystem that includes the microbiota and its natural environment.&#xD;
&#xD;
      Cancer by itself, but also cancer treatments - in particular chemotherapy - induce gut&#xD;
      dysbiosis, impair the constant reparation mechanisms of the gut epithelium, disrupt immune&#xD;
      homeostasis, and stunt immune responsiveness.&#xD;
&#xD;
      The objective of MaaT033 is to (1) prevent the decay of the gut ecosystem (dysbiosis) to&#xD;
      preserve immune homeostasis, (2) restore and optimize the gut ecosystem to full functionality&#xD;
      including its role in repairing the gut epithelium and healthy gut barrier, and (3) maintain&#xD;
      a restored gut ecosystem and fully functional immune homeostasis.&#xD;
&#xD;
      Restoring the full gut ecosystem and its associated microbiota could become an important&#xD;
      therapeutic option to improve clinical outcomes and control adverse events of conventional&#xD;
      approaches, including immunotherapy in cancer patients.&#xD;
&#xD;
      As a first step, MaaT033 capsules containing lyophilized, pooled, full-ecosystem microbiota&#xD;
      in its natural environment are to be tested for their safety and tolerability in&#xD;
      hematological malignant patients, who are exposed to intensive rounds of chemotherapy and&#xD;
      antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 design dose escalation</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of MaaT033-related, treatment-emergent (serious) adverse events, grade &gt;3, as assessed by CTCAE v4.0</measure>
    <time_frame>From treatment start (V1, end of aplasia) to the end of the study (end of consolidation or up to 10 weeks)</time_frame>
    <description>Evaluation of safety and tolerability of MaaT033 in patients with hematologic malignancies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose regimen evaluation</measure>
    <time_frame>From treatment start (V1, end of aplasia) to the end of the study (end of consolidation or up to 10 weeks)</time_frame>
    <description>Activity assessment of the different dose regimens defined as bacterial &quot;engraftment&quot; of the product</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>MaaT033 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MaaT033 capsule</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>MaaT033 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Patients diagnosed with AML defined according to WHO 2016 criteria with ≥20% leukemic&#xD;
             blasts in the bone marrow or with high- risk myelodysplastic syndrome, receiving&#xD;
             intensive chemotherapy&#xD;
&#xD;
          4. Patients healthy enough to likely receive their consolidation or second cycle of&#xD;
             chemotherapy after induction chemotherapy&#xD;
&#xD;
          5. Patients healthy enough to likely receive HSCT&#xD;
&#xD;
          6. Informed written consent&#xD;
&#xD;
          7. Patient recovered from neutropenia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute promyelocytic leukemia (AML-M3)&#xD;
&#xD;
          2. AML secondary to myeloproliferative disorder or chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
          3. Acute myeloid leukemia BCR-ABL1+&#xD;
&#xD;
          4. Active CNS leukemia&#xD;
&#xD;
          5. Patients with a life expectancy of &lt;70 days according to investigator's opinion, or&#xD;
             subject to therapeutic limitations&#xD;
&#xD;
          6. Confirmed or suspected intestinal ischemia&#xD;
&#xD;
          7. Confirmed or suspected toxic megacolon or gastrointestinal perforation&#xD;
&#xD;
          8. Active uncontrolled infection according to the attending physician&#xD;
&#xD;
          9. Any gastro-intestinal bleeding in the past 3 months&#xD;
&#xD;
         10. Any history of gastro-intestinal surgery in the past 3 months&#xD;
&#xD;
         11. Any history of inflammatory bowel disease&#xD;
&#xD;
         12. Any counter-indication to swallow capsules&#xD;
&#xD;
         13. Enrollment in another trial that may interfere with this study&#xD;
&#xD;
         14. Known allergy or intolerance to trehalose, maltodextrin or PEG&#xD;
&#xD;
         15. Women of childbearing potential without efficient contraceptive protection&#xD;
&#xD;
         16. Pregnant or breastfeeding&#xD;
&#xD;
         17. Patients with EBV-negative serology&#xD;
&#xD;
         18. Subject who, in the judgment of the Investigator, is likely to be non-compliant or&#xD;
             uncooperative during the study, or unable to cooperate because of a language problem,&#xD;
             poor mental development;&#xD;
&#xD;
         19. Exclusion period of a previous study&#xD;
&#xD;
         20. Administrative or legal supervision&#xD;
&#xD;
         21. Confirmed positive result to SARS-CoV-2 nasopharyngeal test at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Recher, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>IUCT</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Weinberg, Dr</last_name>
    <phone>+33(0)660907942</phone>
    <email>jweinberg@maat-pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benoit Levast</last_name>
    <phone>+33(0)660907942</phone>
    <email>blevast@maat-pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Thepot, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Sylvain Thepot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Cluzeau, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Cluzeau, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florent Malard, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Florent Malard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Recher, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Christian Recher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiota</keyword>
  <keyword>microbiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

